[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625415":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":63,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":93,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Arkansas Children's Hospital Research Institute","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cases",null,"Participants who have received blinatumomab",{"label":13,"type":10,"description":14,"interventionNames":10},"Controls","Participants who have not received blinatumomab",[16],{"name":17,"affiliation":18,"role":19},"Lauren Appell, MD","Arkansas Children's Research Institute","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","501-364-1494","leappell@uams.edu",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":10},"Stephanie Thomas, RN","501-364-3820",[29,48],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Arkansas Children's","RECRUITING","Little Rock","Arkansas","72202","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-92.28959,34.74648,{"lat":41,"lon":40},[44,46,47],{"name":26,"role":22,"phone":27,"phoneExt":10,"email":45},"chamnesssl@archildrens.org",{"name":17,"role":22,"phone":23,"phoneExt":10,"email":10},{"name":17,"role":19,"phone":10,"phoneExt":10,"email":10},{"facility":49,"status":31,"city":50,"state":33,"zip":51,"country":35,"countryCode":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Arkansas Children's Northwest","Springdale","72762",{"type":38,"coordinates":53},[54,55],-94.12881,36.18674,{"lat":55,"lon":54},[58,62],{"name":59,"role":22,"phone":60,"phoneExt":10,"email":61},"Cristyn Branstetter, MD","479-770-5921","CBranstetter@uams.edu",{"name":59,"role":19,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66],{"name":67,"class":6},"Columbia University","100625415","a-multi-site-study-to-evaluate-the-persistence-of-protective-immunity-to-routine-childhood-vaccinations-in-participants-with-b-allly-who-have-received-blinatumomab-100625415",false,"NCT07422337","A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL\u002FLy Who Have Received Blinatumomab","Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination","BOOSTER","Inclusion Criteria:\n\n* Diagnosis of B-lineage acute lymphoblastic leukemia\u002Flymphoma\n* ≥1 year old and up to 21 years old at diagnosis\n* Informed consent provided, and if applicable, child assent provided\n* Must have received all vaccinations routinely administered during first year of life\n\nExclusion Criteria:\n\n* Relapsed\u002Frefractory disease at any time\n* Received or will require a bone marrow transplant and\u002For cellular therapy\n* Pregnancy","ALL","1 Year","23 Years",{"count":80,"type":81},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia\u002FLymphoma. The main study aims are:\n\n* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL\u002FLy who have received blinatumomab.\n* To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.\n\nResearchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.",[85,86,87,88,89,90,91,92],"B-Cell ALL","B-Cell Acute Lymphoblastic Leukaemia","B-Cell Lymphoblastic Leukemia","B-Cell Lymphoblastic Leukemia\u002FLymphoma","B-cell Acute Lymphoblastic Leukemia (B-ALL)","B-cell Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","B-cell Leukemia",[94,95,96,97],"vaccines","cancer","blinatumomab","immunotherapy","2026-02-23",{"date":100,"type":101},"2026-02-25","ACTUAL",{"date":103,"type":101},"2026-01-13",{"date":105,"type":81},"2029-01",{"name":5,"class":6},2]